SGHT
Sight Sciences, Inc.
Medical - Devices
Market Cap$286M
5Y Perf.-85.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SGHT vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-89.1%
SGHT vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SGHT | NVCR |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $286M | $1.92B |
| Revenue (TTM) | $80M | $674M |
| Net Income (TTM) | $-37M | $-173M |
| Gross Margin | 86.2% | 75.2% |
| Operating Margin | -44.8% | -27.2% |
| Total Debt | $41M | $290M |
| Cash & Equiv. | $92M | $103M |
SGHT vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SGHT
NVCR
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | 100 | 14.3 | -85.7% |
| NovoCure Limited (NVCR) | 100 | 10.9 | -89.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SGHT vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Sight Sciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SGHT
Sight Sciences, Inc.
The Defensive Pick
SGHT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.49, Low D/E 63.8%, current ratio 10.22x
- +85.0% vs NVCR's +1.1%
Best for: sleep-well-at-night
NVCR
NovoCure Limited
The Income Pick
NVCR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 2.20
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs SGHT's -84.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs SGHT's -3.1% |
| Quality / Margins | NVCR | -25.7% margin vs SGHT's -46.8% |
| Stability / Safety | NVCR | Beta 2.20 vs SGHT's 2.49 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SGHT | +85.0% vs NVCR's +1.1% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs SGHT's -32.2%, ROIC -16.4% vs -274.4% |
SGHT vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
SGHT vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGSGHT
SGHTSight Sciences, Inc.
1leads
NVCRNovoCure Limited
2leads
6 Total Categories
CATEGORYLEADERvs SGHTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
NVCR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
SGHT4/6
Risk & VolatilityBeta, volatility, and downside exposure
NVCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SGHT and NVCR each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 8.5x SGHT's $80M. NVCR is the more profitable business, keeping -25.7% of every revenue dollar as net income compared to SGHT's -46.8%.
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $80M | $674M |
| EBITDAEarnings before interest/tax | -$35M | -$165M |
| Net IncomeAfter-tax profit | -$37M | -$173M |
| Free Cash FlowCash after capex | -$25M | -$48M |
| Gross MarginGross profit ÷ Revenue | +86.2% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -44.8% | -27.2% |
| Net MarginNet income ÷ Revenue | -46.8% | -25.7% |
| FCF MarginFCF ÷ Revenue | -31.9% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.5% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +14.3% | -100.0% |
Evenly matched — SGHT and NVCR each lead in 3 of 6 comparable metrics.
Valuation Metrics
NVCR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $286M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $235M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.15x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.69x | 2.92x |
| Price / BookPrice ÷ Book value/share | 4.31x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — SGHT and NVCR each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
NVCR delivers a -50.8% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-59 for SGHT. SGHT carries lower financial leverage with a 0.64x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x.
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | -59.1% | -50.8% |
| ROA (TTM)Return on assets | -32.2% | -16.5% |
| ROICReturn on invested capital | -2.7% | -16.4% |
| ROCEReturn on capital employed | -32.0% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.64x | 0.85x |
| Net DebtTotal debt minus cash | -$51M | $187M |
| Cash & Equiv.Liquid assets | $92M | $103M |
| Total DebtShort + long-term debt | $41M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -14.04x | -96.80x |
Evenly matched — SGHT and NVCR each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SGHT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SGHT five years ago would be worth $1,579 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, SGHT leads with a +85.0% total return vs NVCR's +1.1%. The 3-year compound annual growth rate (CAGR) favors SGHT at -20.5% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -29.3% | +28.3% |
| 1-Year ReturnPast 12 months | +85.0% | +1.1% |
| 3-Year ReturnCumulative with dividends | -49.7% | -75.7% |
| 5-Year ReturnCumulative with dividends | -84.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -84.2% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -20.5% | -37.6% |
SGHT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
NVCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVCR is the less volatile stock with a 2.20 beta — it tends to amplify market swings less than SGHT's 2.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs SGHT's 57.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.49x | 2.20x |
| 52-Week HighHighest price in past year | $9.24 | $20.06 |
| 52-Week LowLowest price in past year | $2.81 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +57.3% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 357K | 1.5M |
NVCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SGHT as "Buy" and NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 82.8% for SGHT (target: $10).
| Metric | SGHTSight Sciences, I… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.67 | $33.50 |
| # AnalystsCovering analysts | 9 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). SGHT leads in 1 (Total Returns). 2 tied.
Best OverallNovoCure Limited (NVCR)Leads 2 of 6 categories
Loading custom metrics...
SGHT vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SGHT or NVCR a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Analysts rate Sight Sciences, Inc. (SGHT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SGHT or NVCR?
Over the past 5 years, Sight Sciences, Inc.
(SGHT) delivered a total return of -84. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus SGHT's -84. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SGHT or NVCR?
By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.
20β versus Sight Sciences, Inc. 's 2. 49β — meaning SGHT is approximately 13% more volatile than NVCR relative to the S&P 500. On balance sheet safety, Sight Sciences, Inc. (SGHT) carries a lower debt/equity ratio of 64% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — SGHT or NVCR?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: Sight Sciences, Inc. grew EPS 28. 2% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SGHT or NVCR?
NovoCure Limited (NVCR) is the more profitable company, earning -20.
8% net margin versus -49. 7% for Sight Sciences, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -48. 0% for SGHT. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SGHT or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SGHT or NVCR better for a retirement portfolio?
For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +30. 3%, SGHT: -84. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SGHT and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SGHT: 12.5% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.